Physician profile
Adam Tran
NPI 1700591484
$7,393.57
in general payments reported to CMS, 2019-2025
22 companies · $4,738 in 2025
The $4,738 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,655 · 2025: $4,738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,355 · Education: $38.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,355.40 |
| Education | $38.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,337.37 | 2024-2025 | Spravato, Invega Sustenna |
| Abbvie INC. | $924.92 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $787.85 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Vanda Pharmaceuticals INC. | $686.40 | 2024-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $684.31 | 2024-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $512.42 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $465.46 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $449.84 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $303.97 | 2024-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $290.69 | 2024-2025 | Rexulti |
| Axsome Therapeutics, INC. | $198.51 | 2025 | Auvelity, Sunosi |
| Biogen, INC. | $165.78 | 2025 | Zurzuvae |
| Noven Therapeutics, LLC | $144.51 | 2024-2025 | Xelstrym |
| Takeda Pharmaceuticals U.S.A., INC. | $114.08 | 2024-2025 | Trintellix |
| Corium, LLC | $74.60 | 2024-2025 | Azstarys |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $64.33 | 2024-2025 | Sublocade |
| Tris Pharma INC | $56.05 | 2024 | Dyanavel Xr |
| Luye Pharma (USA) LTD. | $38.33 | 2025 | Erzofri Extended-Release |
| Ironshore Pharmaceuticals INC. | $28.93 | 2024 | |
| Almatica Pharma LLC | $27.76 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $23.73 | 2025 | Jornay Pm |
| Glaxosmithkline, LLC. | $13.73 | 2024 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Tran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.